Changing trends in infectious disease in heart transplantation

J Heart Lung Transplant. 2010 Mar;29(3):306-15. doi: 10.1016/j.healun.2009.08.018. Epub 2009 Oct 22.

Abstract

Background: During the past 25 years, advances in immunosuppression and the use of selective anti-microbial prophylaxis have progressively reduced the risk of infection after heart transplantation. This study presents a historical perspective of the changing trends of infectious disease after heart transplantation.

Methods: Infectious complications in 4 representative eras of immunosuppression and anti-microbial prophylaxis were analyzed: (1) 38 in the pre-cyclosporine era (1978-1980), (2) 72 in the early cyclosporine era (1982-1984), where maintenance immunosuppression included high-dose cyclosporine and corticosteroid therapy; (3) 395 in the cyclosporine era (1988-1997), where maintenance immunosuppression included cyclosporine, azathioprine, and lower corticosteroid doses; and (4) 167 in the more recent era (2002-2005), where maintenance immunosuppression included cyclosporine and mycophenolate mofetil.

Results: The overall incidence of infections decreased in the 4 cohorts from 3.35 episodes/patient to 2.03, 1.35, and 0.60 in the more recent cohorts (p < 0.001). Gram-positive bacteria are emerging as the predominant cause of bacterial infections (28.6%, 31.4%, 51.0%, 67.6%, p = 0.001). Cytomegalovirus infections have significantly decreased in incidence and occur later after transplantation (88 +/- 77 days, pre-cyclosporine era; 304 +/- 238 days, recent cohort; p < 0.001). Fungal infections also decreased, from an incidence of 0.29/patient in the pre-cyclosporine era to 0.08 in the most recent era. A major decrease in Pneumocystis jiroveci and Nocardia infections has also occurred.

Conclusions: The overall incidence and mortality associated with infections continues to decrease in heart transplantation and coincides with advances in immunosuppression, the use of selective anti-microbial prophylaxis, and more effective treatment regimens.

MeSH terms

  • Adult
  • Anti-Bacterial Agents / therapeutic use
  • Antiviral Agents / therapeutic use
  • Bacterial Infections / epidemiology
  • Bacterial Infections / prevention & control
  • Cohort Studies
  • Communicable Diseases / epidemiology*
  • Female
  • Heart Diseases / surgery*
  • Heart Transplantation* / immunology
  • Heart Transplantation* / mortality
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Incidence
  • Male
  • Middle Aged
  • Mycoses / epidemiology
  • Mycoses / prevention & control
  • Opportunistic Infections / epidemiology*
  • Opportunistic Infections / immunology
  • Postoperative Complications / epidemiology*
  • Postoperative Complications / microbiology
  • Postoperative Complications / virology
  • Retrospective Studies
  • Virus Diseases / epidemiology
  • Virus Diseases / prevention & control

Substances

  • Anti-Bacterial Agents
  • Antiviral Agents
  • Immunosuppressive Agents